Drugs / Abituzumab
Abituzumab
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01327313 | Jan 2011 → Jul 2012 | cancer | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT00848510 | Feb 2009 → Nov 2013 | colorectal cancer | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT00958477 | Oct 2008 → Sep 2010 | metastatic carcinoma in the bone, prostate cancer | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01008475 | Oct 2009 → Apr 2015 | colorectal cancer | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03688230 | Apr 2019 → Dec 2020 | colorectal cancer | SFJ Pharmaceuticals X, LTD. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02745145 | May 2016 → May 2018 | interstitial lung disease | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01360840 | Apr 2011 → Apr 2013 | metastatic prostate carcinoma | EMD Serono | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abituzumab | “This study is intended to test an experimental drug called EMD 525797 (Abituzumab).” NCT00848510 ↗ |
| Known as | DI17E6 | “A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone...” PMID 23791392 ↗ Jun 2013 |
| Known as | EMD 525797 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01360840 ↗ |
| Modality | Monoclonal antibody | “A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone...” PMID 23791392 ↗ Jun 2013 |
| Route | Intravenous | “Abituzumab will be administered as an intravenous infusion” NCT00848510 ↗ |